Resverlogix Corp.
RVXCF
Rank in Stocks
#26573
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Share Price
$0.05548
Last synced: 2026-11-09
Market Cap
$19.50M
Change (1 day)
14.39%
Change (1 year)
-23.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Resverlogix Corp. (RVXCF)
Category
Healthcare
EPS for Resverlogix Corp. (RVXCF)
EPS as of June 2026 TTM: $-0.03
According to Resverlogix Corp.'s latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $-0.03, equal to its 2024 EPS of $-0.03.
EPS history for Resverlogix Corp. from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.03 | 8.67% |
| 2025 | $-0.03 | 0.36% |
| 2024 | $-0.03 | 94.37% |
| 2022 | $-0.01 | -85.80% |
| 2021 | $-0.10 | -117.54% |
| 2020 | $0.57 | -165.52% |
| 2019 | $-0.87 | 107.14% |
| 2018 | $-0.42 | -4.55% |
| 2017 | $-0.44 | 120.00% |
| 2016 | $-0.20 | -9.09% |
| 2015 | $-0.22 | -68.12% |
| 2014 | $-0.69 | -218.97% |
| 2013 | $0.58 | 100.00% |
| 2012 | $0.29 | 625.00% |
| 2011 | $0.04 | -105.97% |
| 2010 | $-0.67 | 9.84% |
| 2009 | $-0.61 | -44.04% |
| 2008 | $-1.09 | 57.97% |
| 2007 | $-0.69 | 155.56% |
| 2006 | $-0.27 | 92.86% |
| 2005 | $-0.14 | 59.27% |
| 2004 | $-0.09 | 83.89% |
| 2003 | $-0.05 | -16.29% |
| 2002 | $-0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -48,136.81% |
US
|
|
| $-7.07 | 21,587.12% |
US
|
|
| $-5.29 | 16,126.99% |
AU
|
|
| $12.88 | -39,609.51% |
BE
|
|
| $21.56 | -66,234.97% |
NL
|
Questions about Resverlogix Corp.'s earnings per share (EPS)
What is Resverlogix Corp.'s earnings per share (EPS)?
Resverlogix Corp.'s earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2026.
What was Resverlogix Corp.'s earnings per share (EPS) in 2025?
In 2025, Resverlogix Corp.'s earnings per share (EPS) was $-0.03, compared with $-0.03 in 2024.
How has Resverlogix Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Resverlogix Corp.'s earnings per share (EPS) was highest in 2020 ($0.57) and lowest in 2021 ($-0.10).
How does Resverlogix Corp.'s earnings per share (EPS) compare with similar companies?
Resverlogix Corp.'s earnings per share (EPS) ($-0.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.